Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Fact check: 13% of Belgians take antidepressants
1. Summary of the results
The statement is accurate but requires more precision. Specifically, 13.3% of Belgian adults used antidepressants at least once in 2021 [1] [1]. This represents over one million Belgians [2]. The usage shows significant gender disparity, with 13 out of 100 women compared to 7 out of 100 men using antidepressants [3].
2. Missing context/alternative viewpoints
Several important contextual elements are missing from the original statement:
- Temporal trends: There has been an 8% growth in antidepressant use between 2019-2023 [3], indicating a rising trend
- Regional variations: Usage rates differ across Belgium, with Flanders showing lower consumption compared to Wallonia and Brussels [2]
- International context: While Belgium exceeds the European average by about 10% [3], it's not among the highest consumers. Countries including Iceland, Portugal, UK, Sweden, and Spain have higher usage rates [1]
- Usage pattern: The statistic refers to people who used antidepressants "at least once" in a year [1], not necessarily regular users
3. Potential misinformation/bias in the original statement
The original statement, while technically correct, could be misleading in several ways:
- It presents the figure without temporal context, potentially masking the significant recent increase [3]
- It doesn't acknowledge the substantial gender disparity in usage rates [3]
- By presenting Belgium's figure in isolation, it might create an impression of exceptionally high usage, when several European countries actually have higher rates [1]
- The statement doesn't specify that this refers to adult population only, which could lead to misinterpretation of the total population statistics [1]
This type of data could be used by various stakeholders for different purposes:
- Pharmaceutical companies might use it to justify market expansion
- Mental health advocates might use it to highlight the need for alternative treatments
- Healthcare policymakers might use it to compare Belgium's mental health situation with other European countries